Financiere des Professionnels Fonds d investissement inc. Has $24.26 Million Stake in Becton, Dickinson and Company $BDX

Key Points

• Financiere des Professionnels Fonds d investissement inc. increased its Becton, Dickinson and Company stake by 10.9% in the fourth quarter, ending with 125,024 shares valued at about $24.26 million.
• Institutional ownership remains high, with 86.97% of BDX shares held by hedge funds and other institutions. Several other investors also boosted their positions in recent quarters.
• Analysts remain mixed on BDX: the consensus rating is Hold with a target price of $183.64, while the company also reported better-than-expected quarterly earnings and declared a $1.05 quarterly dividend.

Financiere des Professionnels Fonds d investissement inc. grew its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 10.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,024 shares of the medical instruments supplier's stock after purchasing an additional 12,264 shares during the period. Becton, Dickinson and Company comprises about 1.4% of Financiere des Professionnels Fonds d investissement inc.'s investment portfolio, making the stock its 13th biggest position. Financiere des Professionnels Fonds d investissement inc.'s holdings in Becton, Dickinson and Company were worth $24,263,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of BDX. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC boosted its stake in Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier's stock worth $1,827,000 after buying an additional 1,354 shares in the last quarter. United Bank boosted its stake in Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier's stock worth $887,000 after buying an additional 993 shares in the last quarter. Marshall Wace LLP boosted its stake in Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier's stock worth $5,491,000 after buying an additional 25,022 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in Becton, Dickinson and Company by 34.7% during the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier's stock worth $4,048,000 after buying an additional 6,058 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BDX shares. Zacks Research upgraded shares of Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research note on Friday, April 10th. Stifel Nicolaus decreased their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Piper Sandler decreased their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a "neutral" rating on the stock in a research note on Friday, April 17th. Argus decreased their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating on the stock in a research note on Monday, March 23rd. Finally, Evercore lifted their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $183.64.

Insider Activity

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business's stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company's stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,913 shares of company stock valued at $426,806 over the last three months. Insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $148.14 on Thursday. The stock has a 50-day simple moving average of $150.40 and a 200 day simple moving average of $174.56. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The stock has a market capitalization of $40.82 billion, a price-to-earnings ratio of 37.50, a P/E/G ratio of 10.76 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion during the quarter, compared to analysts' expectations of $4.67 billion. During the same period in the previous year, the business posted $3.35 earnings per share. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company's payout ratio is currently 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.